7XP logo

Organon DB:7XP Stock Report

Last Price

€14.43

Market Cap

€3.7b

7D

3.8%

1Y

11.0%

Updated

28 Dec, 2024

Data

Company Financials +

Organon & Co.

DB:7XP Stock Report

Market Cap: €3.7b

7XP Stock Overview

Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. More details

7XP fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health1/6
Dividends4/6

Rewards

Trading at 84.1% below our estimate of its fair value

Earnings grew by 122.4% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Interest payments are not well covered by earnings

Earnings are forecast to decline by an average of 8.3% per year for the next 3 years


My Notes

Capture your thoughts, links and company narrative

Organon & Co. Competitors

Dermapharm Holding

XTRA:DMP

€2.1b

Merck KGaA

XTRA:MRK

€60.8b

PharmaSGP Holding

XTRA:PSG

€292.6m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of share price highs, lows and changes for Organon
Historical stock prices
Current Share PriceUS$14.43
52 Week HighUS$20.77
52 Week LowUS$12.47
Beta0.70
1 Month Change-5.07%
3 Month Change-15.76%
1 Year Change10.96%
3 Year Change-44.71%
5 Year Changen/a
Change since IPO-43.48%

Recent News & Updates

Recent updates

Shareholder Returns

7XPDE PharmaceuticalsDE Market
7D3.8%1.4%0.5%
1Y11.0%-16.3%7.2%

Return vs Industry: 7XP exceeded the German Pharmaceuticals industry which returned -16.3% over the past year.

Return vs Market: 7XP exceeded the German Market which returned 7.2% over the past year.

Price Volatility

Is 7XP's price volatile compared to industry and market?
7XP volatility
7XP Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7XP has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 7XP's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202010,000Kevin Aliwww.organon.com

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.

Organon & Co. Fundamentals Summary

How do Organon's earnings and revenue compare to its market cap?
7XP fundamental statistics
Market cap€3.72b
Earnings (TTM)€1.25b
Revenue (TTM)€6.15b

3.0x

P/E Ratio

0.6x

P/S Ratio

Is 7XP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7XP income statement (TTM)
RevenueUS$6.41b
Cost of RevenueUS$2.68b
Gross ProfitUS$3.73b
Other ExpensesUS$2.43b
EarningsUS$1.30b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.05
Gross Margin58.26%
Net Profit Margin20.30%
Debt/Equity Ratio1,774.6%

How did 7XP perform over the long term?

See historical performance and comparison

Dividends

7.4%

Current Dividend Yield

22%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 20:08
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Organon & Co. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
Navann Ty DietschiBNP Paribas Exane